Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Paraxanthine** is a naturally occurring compound and the primary metabolite of caffeine in humans. Enfinity, the branded form of paraxanthine, is marketed as a safer and more consistent alternative to caffeine for use as an energy and focus ingredient in dietary supplements. Rather than being metabolized from caffeine, it is delivered directly, bypassing the intermediate compounds (theophylline and theobromine) and purportedly reducing caffeine-associated side effects like jitters, anxiety, and crashes. Enfinity is used in energy, cognition, and performance supplements, supported by clinical and preclinical research[2][10]. Its proposed mechanism is central nervous system stimulation, similar to caffeine, but with a claimed smoother effect and reduced bitterness, making it attractive for product formulation. It is promoted for boosting energy, wakefulness, reaction speed, focus, mood, and thermogenesis[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paraxanthine.